by Travis Johnson, Stock Gumshoe | December 5, 2014 1:01 am
This is premium content. To view this article (and to have full access to the rest of our articles), sign up. Already a member? Log in.
Source URL: https://www.stockgumshoe.com/reviews/transformational-technology-alert/how-a-company-youve-never-heard-of-could-end-alzheimers-disease-and-save-americas-financial-future/
Copyright ©2024 Stock Gumshoe unless otherwise noted.
My father died at 92, my mother at 96 and for the last 2 ~3 years of their lives both had Alzheimer’s (Old Timers?) and neither was really aware of it. It appears that this has perhaps skipped a generation as to date none of my siblings has shown signs of it. One older brother died a bit early of cancer at 62 and our sister at 73 (we thought she would outlive us all). My eldest brother at 91 exhibits no hint of it (he’s still hanging in there). My real observation is that only the people around someone with that affliction suffers from it. The person that has it (short term memory loss being the main culprit) doesn’t know they have it and most probably doesn’t really care. I could relate stories (some humorous, some not so) about my dad and my mom and their actions/reactions to the affliction but it would probably serve little purpose. I doubt either of them knew they had Alzheimer’s. I’ll not be pouring money into Mr. Cox’es pet stock.
I can’t comment on Anavex as an “investment,” but as a potential “cure” for Alzheimer’s,, it’s a long shot with the trajectory calculated in light-years. If it showed modest positive cognitive results in preclinicals, that was likely due to the aricept component, which does indeed have those properties, to a modest degree. Lots of people think there has to be something else in AD besides the beta amyloid hypothesis, and lots and lots and LOTS of outfits are poking into that. The “success” ratio in AD trials is about 1 in 250, and even that depends on the definition of “success.” I can proclaim that it won’t be Anavex that takes their drug through the painful stages to approval and market, even if there are some positive Phase 2 results. So far they have established comparative safety and absolutely nothing more. On the other hand, some pharmas with deeper pockets have some decent prospects in the AD field – Biogen Idec and Eli Lilly amont them. I’m keeping an eye on the overall field & will do an update in the new year.
AVXL-Enrolls first patient http://globenewswire.com/news-release/2014/12/16/691648/10112506/en/Anavex-Begins-Enrollment-of-Alzheimer-s-Patients-in-Phase-2a-Clinical-Trial-of-ANAVEX-2-73-and-ANAVEX-PLUS.html No Position. Best-Benjamin
How about Alexander Lynch and his memory diet of fruit and vegetables??
40 bucks will let you in on the secrets.
He advises to get in pronto as “big pharma” is threatening to do him in.
Anybody know anything about this? A tutti-fruity shake can’t hurt-if you remember where you put the info.
AVXL-I was just noticing that the equity has doubled in the last copule months. Best-Ben
Glad I didn’t listen to the doubters…. AVLXL’s initial Phase 2 positive results reported today is very welcome news. It’s still a long road but now there’s a big light at the end of the tunnel for shareholders and especially Alzheimer sufferers.
Roger…I believe you may be a new Irregular…Welcome!
I wish to invite you to join us on the current bio-thread and and share ZKSS’s comment:
Comment Link: http://www.stockgumshoe.com/2015/07/the-second-coming-of-transenterix/comment-page-5/#comment-4496869
Author: Dr. KSS, MD PhD
Comment:
Sigma receptors are merely a subtype of opioid receptor originally of interest because they may attenuate glutamate and NMDA-mediated excitotoxicity. The recent dextromethorphan/quinidine combo that seems to help with pseudobulbar affect is mediated via sigma one. Molecular evidence that sigma has actions that affect tau protein and beta amyloid is flimsy and circumstantial. And as Peter Tilton pointed out, it is offensive to all people of reason to use the mini-mental status exam tp appraise Alzheimer disease patients. For me, some stocks have little “shame” sashes around them, and I’d not want to own them even if they are profitable. I have read over about half the world’s medical literature on sigma one over the last couple of evenings. This company is on skating on imaginary ice.
Best2YouAlways-Ben